Eyeworld

MAY 2018

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: http://digital.eyeworld.org/i/978371

Contents of this Issue

Navigation

Page 86 of 86

For additional safety information, see accompanying Brief Summary of Safety Information on the adjacent page and Full Prescribing Information on Xiidra-ECP.com. For additional safety information, see accompanying Brief Summary of Safety Information For additional safety information, see accompanying Brief Summary of Safety Information ©2018 Shire US Inc., Lexington, MA 02421. 1-800-828-2088. All rights reserved. SHIRE and the Shire Logo are trademarks or registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affi liates. Marks designated ® and ™ are owned by Shire or an affi liated company. S38464 03/18 SIGNS & SYMPTOMS HAVE MET THEIIR MATCH Xiidra is the only treatment FDA-approved to treat both signs and symptoms of Dry Eye Indication Xiidra ® (lifi tegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). Important Safety Information Xiidra is contraindicated in patients with known hypersensitivity to lifi tegrast or to any of the other ingredients. In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface. Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. Safety and effi cacy in pediatric patients below the age of 17 years have not been established. Xiidra is contraindicated in patients with known hypersensitivity to lifi tegrast or to any of the other ingredients. AT 12 WEEKS in 3 of 4 trials Proven to treat signs of inferior corneal staining AT 6 AND 12 WEEKS in all 4 trials Proven to treat symptoms of eye dryness Check it out at Xiidra-ECP.com Four randomized, double-masked, 12-week trials evaluated the effi cacy and safety of Xiidra versus vehicle as assessed by improvement in the signs (measured by Inferior Corneal Staining Score on a scale of 0 to 4) and symptoms (measured by Eye Dryness Score on a scale of 0 to 100) of Dry Eye Disease (N=2133). Xiidra is the only prescription eye drop to show symptom relief from eye dryness in 2 out of 4 clinical trials IN AS LIITTLE AS 2 WEEKS

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - MAY 2018